January 27, 2009 — Geron Corp announced it has received US Food and Drug Administration (FDA) approval for a phase 1 trial of GRNOPC1, a cell therapy derived from human embryonic stem cells (hESC), in ...

Sensorineural hearing loss (SNHL) remains a global health challenge with limited regenerative therapeutic options. This ...

HexemBio has launched with a seed round led by Draper Associates to advance a blood stem cell rejuvenation therapy backed by Robert Langer.

A feat once deemed impossible has been accomplished --- the deprogramming of a fully differentiated human cell into an embryonic stem cell. Two laboratories report a breakthrough that may one day ...

Treatment represents a new approach that could potentially restore brain cells lost due to Parkinson’s disease ...

Geron Corp., the company that started the first U.S.-approved trial of human embryonic stem cells, fell the most in more than 11 years after research costs and regulatory complexities caused it to end ...

Over the last two and a half decades, advancements in stem cell biology and immunology have improved the potential for cell therapy as a treatment for diabetes. Stem cells from different sources can ...